Jim Cramer Won't Touch POET. The Reddit Crowd Thinks He's Wrong.

POET reported Q1 FY2026 revenue of $503,389, beating the $347,970 estimate, but the business remains deeply pre-revenue at a $2.27 billion market cap and a $12.34 million quarterly net loss. The stock was hit hard after Marvell cancelled all Celestial AI purchase orders on April 27, triggering a 45% one-day drop and subsequent class action lawsuits, though bulls are now focused on a $50 million Lumilens purchase order and a potential $40 year-end target. The investment debate centers on whether the Malaysia ramp, Lumilens framework, and 30,000-engine shipment target can offset dilution, legal risk, and execution uncertainty.

Analysis

POET is no longer trading like a pre-revenue story; it is trading like a financing and disclosure-risk event wrapped inside an AI packaging theme. The key market dynamic is that the equity has already re-rated on narrative optionality, so the next leg is less about TAM and more about whether management can convert a headline purchase order into a visible manufacturing cadence without another credibility shock. In that regime, every incremental delay has asymmetric downside because the stock’s implied “prove-it” window is being measured in quarters, not years.

The second-order effect is that suppliers and adjacent photonics names may benefit if POET’s customer set diversifies, but the same controversy also raises diligence standards across the sector. Any other company touting optical interposer, co-packaged optics, or AI packaging wins will likely face a tougher market multiple until it can show either audited backlog, milestone-based cash conversion, or a cleaner customer concentration profile. That makes the trade potentially more about relative quality than absolute industry demand.

The contrarian read is that the bear case may already be crowded on fundamentals while the bull case remains crowded on reflexive momentum. The setup is dangerous because sentiment can overshoot in either direction: a single credible manufacturing update could trigger another squeeze, but a missed delivery, customer ambiguity, or equity raise would probably compress the multiple faster than investors expect. The market is effectively pricing a binary transition from story-stock to industrial supplier; most of the value is in execution, yet the stock still behaves as if execution risk is optional.

Key Decisions for Investors

• Avoid outright long exposure to POET until management shows at least one more quarter of order conversion and shipment visibility; the current risk/reward is poor because downside from another credibility event can be 30-50% while upside from ‘good enough’ execution is likely incremental over 1-2 quarters.
• For traders willing to express a bearish view, buy POET puts or put spreads with 30-60 day tenor after any momentum bounce; the setup favors event-driven downside if the market revisits the Marvell/disclosure overhang or questions the Lumilens economics.
• Pair trade idea: long AAOI vs short POET for 1-3 months. AAOI captures AI optics upside with materially less balance-sheet and customer-concentration risk, while POET remains the cleaner sentiment short if investors rotate from story to fundamentals.
• If you want a long, use a small-sized call spread on POET only after confirmation of production ramp milestones or customer shipment disclosures; the right way to own it is as a convex squeeze trade, not a core position.
• Watch for equity issuance or warrant-related dilution over the next 1-2 quarters; any capital raise at a discount would be the clearest signal that the market is underwriting growth faster than cash generation can support.